The story has been updated to include comments from Qiagen's conference call.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues increased 9 percent year over year as both instruments and consumables and related sales bounced in the double digits.

The company also announced its first share buyback program with plans to repurchase up to $100 million in Qiagen shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.